Biopathologic features and clinical significance of micrometatasis in the lymph node of early gastric cancer

Table 3 Recurrence and associated factors (n = 90)

	No recurred (n = 84)	Recurred (n = 6)	P value
Age (yr)	57.8 ± 12.0	64.8 ± 7.4	0.159
Sex			1.000
Male	52 (61.9)	4 (66.7)
Female	32 (38.1)	2 (33.3)
Depth of invasion			1.000
Mucosa	12 (14.3)	0 (0)
Submucosa	72 (85.7)	6 (100)
Tumor size (cm)	4.7 ± 2.5	3.7 ± 1.27	0.321
Histology			0.681
Differentiated	44 (52.4)	4 (66.7)
Undifferentiated	40 (47.5)	2 (33.3)
Lauren			0.396
Intestinal	49 (58.3)	5 (83.3)
Diffuse, mixed	35 (41.7)	1 (16.7)
Lymphovascular invasion			0.032
Absent	40 (47.6)	0 (0)
Present	44 (52.4)	6 (100)
Metastatic LNs (n)	2.0 ± 1.3	2.2 ± 1.2	0.816
Classification of nodal metastasis			0.041
Micrometastasis	37 (44.0)	0 (0)
Macrometastasis	47 (56.0)	6 (100)
Japanese N2 station involvement1			0.127
No	58 (85.3)	2 (50.0)
Yes	10 (14.7)	2 (50.0)
Main tumor burden in LN (mm)	3.0 ± 4.1	4.0 ± 1.5	0.594
Pattern of metastasis in LNs			0.450
Single cluster	28 (33.3)	4 (66.7)
Multiple cluster	54 (64.3)	1 (16.7)
Diffuse	2 (2.4)	1 (16.7)
Location of metastasis in LNs			0.090
Marginal sinus	31 (36.9)	0 (0)
Non marginal sinus	53 (63.1)	6 (100)
Gastric resection			1.000
Open subtotal	63 (75.0)	4 (66.7)
Open total	7 (8.3)	1 (16.7)
LADG	14 (16.7)	1 (16.7)
Lymph node dissection			1.000
D1 + β	28 (33.3)	2 (33.3)
D2	56 (66.7)	4 (66.7)
Dissected LNs (n)	37.4 ± 13.8	41.0 ± 16.4	0.538
Adjuvant chemotherapy			0.660
No	30 (35.7)	1 (16.7)
Yes	54 (64.3)	5 (83.3)
Ki-67 (primary tumor)1
Positive cell	61.3% ± 22.1%	58.3% ± 24.6%	0.748
TUNEL (primary tumor)1
Positive cell	3.6% ± 3.9%	4.6% ± 2.2%	0.552
Ki-67 (lymph node)1
Positive cell	35.0% ± 23.5%	35.0% ± 10.8%	0.996
TUNEL (lymph node)1
Positive cell	2.3% ± 3.2%	2.8% ± 1.1%	0.720

¹Available data only. Data are expressed as absolute numbers (percentage) or mean ± SD. LN: Lymph node; LADG: Laparoscopically assisted distal gastrectomy; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling.